Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research News Agency

Yesterday•Zacks Investment Research

Stocks Medium Importance Neutral

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.

Related Symbols 1

A ARCT ARCT

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #2,465

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Comments

User Menu